International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)
Study Details
Study Description
Brief Summary
InVITE is funded by NIAID and is conducted in multiple international sites (approximately 20 sites across 7 countries).
This is a study of adults who receive locally available COVID-19 vaccines through local vaccination programs. Persons will be enrolled within one day (before or after) of receipt of a COVID-19 vaccine. The study will enroll participants who receive COVID-19 vaccination at local clinics and/or study sites.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
This is a multicenter study of COVID-19 vaccine immunogenicity and durability, and breakthrough serious acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in people who receive a COVID-19 vaccine through their country's national vaccination programs. Participants will be enrolled upon signing the informed consent within a day of receipt of a COVID-19 vaccine (before or after). The study team will not be administering the vaccine; receipt of vaccine will be provided through each country's vaccine program. Blood specimens will be collected to measure the immune response to the vaccine. Participants may be asked to contact study staff at any time during the study for evaluation if they develop symptoms consistent with SARS-CoV-2 infection, at which time they will be counseled about the need for a medical evaluation that may include collection of an upper airway swab for diagnosis (and research) and a blood sample for research. Infections will be confirmed by molecular or antigen (Ag) testing at the time of symptoms, and swabs will be collected and stored for viral sequencing and analyses.
Study Design
Outcome Measures
Primary Outcome Measures
- 1. To characterize immunogenicity (by measurement of anti-Spike [S] antibody [Ab]) of available COVID-19 vaccines in the overall study population, in each of the countries and in defined subgroups [2 months]
Measured by amount of Anti-S Ab at 2 months after completion of vaccine regimen.
Secondary Outcome Measures
- Evaluate duration of immunogenicity [1 day, 2 months, 10 months]
Measured by Anti-S Ab at different specific timepoints
- Evaluate immunogenicity in predefined subgroups (by age, body mass index [BMI], comorbidities, HIV, breakthrough infection, or evidence of prior infection with SARS-CoV-2). [1 day, 2 months, 10 months]
Measured by levels of Anti-S Ab in predefined subgroups.
- Characterize virus causing breakthrough infections using viral genomic sequencing. [1 day]
Measured from sequencing to characterize SARS-CoV-2 variants
- Compare immunogenicity between different vaccines. [2 months]
Measured by Anti-S Ab levels at 2 months post-vaccine regimen
- Evaluate infection rates after vaccination. [1 day]
Measured by levels of anti-nucleocapsid Ab
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years of age or older.
-
Ability to provide informed consent.
-
Enrollment within one day (before or after) of receipt of COVID-19 vaccine.
-
Willingness to be evaluated (including collection of blood and nasopharyngeal samples) during the prescribed study visits and/or during acute illness consistent with SARS-CoV-2 infection during the study period.
-
Willingness to allow storage of biological samples for research testing as outlined in this protocol.
Exclusion Criteria:
-
Any acute or chronic condition that, in the opinion of the investigator, is a contraindication to participation in this study; for example, acute febrile illness.
-
Inability to comply with study visits.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Institute for Biomedical Research/Institut National de Recherche Biomédicale (INRB) | Gombe | Kinshasa | Congo, The Democratic Republic of the | |
| 2 | Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI) | Conakry | Guinea | ||
| 3 | National Institute of Health Research and Development (NIHRD), Ministry of Health, Republic of Jakarta - RSU Kabupaten Tangerang | Tangerang | Indonesia | ||
| 4 | Partnership for Research in Vaccines and Infectious Diseases in Liberia (PREVAIL) - Duport Road Health Center | Monrovia | Liberia | ||
| 5 | University Clinical Research Center (UCRC) University of Sciences, Techniques and Technologies of Bamako | Bamako | Mali | ||
| 6 | LaRed Network | Mexico City | Mexico | ||
| 7 | LaRed Network | Monterrey | Mexico | ||
| 8 | LaRed Network | Oaxaca | Mexico | ||
| 9 | LaRed Network | Tapachula | Mexico | ||
| 10 | Onom Foundation and Liver Center | Ulaanbaatar | Mongolia | 17011 |
Sponsors and Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
- Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI)
- National Institute of Health Research and Development, Ministry of Health Republic of Indonesia
- Partnership for Research on Ebola Virus in Liberia (PREVAIL)
- University Clinical Research Center, Mali
- National Institute of Medical Sciences and Nutrition, Salvador Zubiran
- Onom Foundation and Liver Center
Investigators
- Study Director: Renee Ridzon, MD, National Institute of Allergy and Infectious Diseases (NIAID)
- Study Director: Irini Sereti, MD, National Institute of Allergy and Infectious Diseases (NIAID)
- Study Director: Sally Hunsberger, PhD, National Institute of Allergy and Infectious Diseases (NIAID)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- InVITE 01